ReviewCancers2023
Treatment of Recurrent Giant Cell Tumor of Bones: A Systematic Review.
Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 12 citations in OpenAlex.
- Extensive Giant Cell Tumor Involving Entire Tibia with Talar Extension and Pulmonary Metastases: Successful Limb Preservation with Denosumab and Angioembolization.Journal of orthopaedic case reports · 2026Article
- Reawakening of a Giant Cell Bone Tumor after 40 Years of Silence: A Rare Case Report.Journal of orthopaedic case reports · 2026Article
- Freezing nitrogen ethanol composite as an alternative to liquid nitrogen in giant cell tumor cryotherapy: a case report and literature review.International journal of surgery case reports · 2026Article
- Patient-specific Distal Tibia Prosthesis for Reconstruction in a Case of Recurrent Giant Cell Tumor - A Case Report.Journal of orthopaedic case reports · 2026Article
- Metachronous multicentric giant cell tumor of bone with pulmonary metastases: a case report with 20-year follow-up.Frontiers in oncology · 2026Article
- Patterns and Timing of Local Recurrence in Benign Bone Tumors.The Iowa orthopaedic journal · 2026Article
- Soft tissue recurrence in giant cell tumor of Bone: A comprehensive review of pathogenesis, imaging features, and clinical management.Journal of bone oncology · 2025Review
- Skip Lesion in Distal Femur with Recurrent Giant Cell Tumor of the Proximal Femur: A Very Rare Case Managed with Excision, Megaprosthesis Reconstruction, and Bone Cement Curettage.Journal of orthopaedic case reports · 2025Article
- Functional Outcomes of Surgical Treatment for Giant Cell Tumors around the Knee.Journal of orthopaedic case reports · 2025Article
- Article
- Percutaneous radiofrecuency thermal ablation for management of recurrent bone giant cell tumour.Quantitative imaging in medicine and surgery · 2024Article
- Denosumab combined with en bloc resection and arthrodesis for recurrent grade 3 giant cell tumor of bone in distal radius.Journal of orthopaedic surgery and research · 2024Article
- Article
- Giant Cell Tumor of the Cervical Axis Treated With Anterior-Posterior Surgery and Denosumab: A Ten-year Follow-up Case Report.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The giant cell tumor of bones (GCTB) is a benign bone tumor with high postoperative recurrence potential. No specific treatment protocol has been developed to date in case of tumor recurrence, and the kind of re-operative surgery depends upon the surgeon's preferences. The aim of this systematic review is to determine the second recurrence rate and the respective functional results of the available treatment options applied to recurrent GCTB. Medline/PubMed and Scopus were searched to identify articles published until March 2023. Twelve studies fulfilled the inclusion criteria, comprising 458 patients suffering from recurrent GCTB. The overall incidence of second recurrence was 20.5%, at a mean interval of 28.8 months after the first surgery, and it was more evident after intralesional curettage (IC) surgery than en-bloc resection (EBR) (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.